Reaching for best practices in food oral immunotherapy

Wasserman, Richard L.; Jones, D. H.; Windom, Hugh; Bajowala, Sakina; Carr, Warner; Chacko, Thomas; Detjen, Paul; Fergeson, Jennifer; Fitzhugh, David J.; Hague, Angela; Ly, Jean; Mayer, Chad; Pence, Deanna M.; Shah, Atul

doi:10.1016/j.anai.2019.05.002

Search citation statements

Order By: Relevance

Paper Sections

Select...

Maintenance Protocols Including Activity Limitations1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

2022

Publication Types

Select...

Article6

Relationship

Self Cite1

Independent5

Authors

Journals

Cited by 16 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Maintenance doses range from <100 mg of treatment food protein to 2000 mg of nut protein, 4000 mg of wheat protein, 5000 mg of egg protein, and 8000 mg of cow’s milk protein. 9 …”

Section: Maintenance Protocols Including Activity Limitationsmentioning

confidence: 99%

Long term oral immunotherapy management and assessment of success

Wasserman¹

2022

Journal of Food Allergy

Self Cite

View full text Add to dashboard Cite

There is limited data addressing the optimal dose, dosing frequency, and duration of OIT maintenance. Using higher maintenance doses, more frequent dosing, and a long dosing duration makes it more likely that sustained unresponsiveness will be achieved but also increases the burden of care on the OIT patient and family. The OIT maintenance regimen should be individualized based on the treatment goals of the patient and family.

show abstract

“…Maintenance doses range from <100 mg of treatment food protein to 2000 mg of nut protein, 4000 mg of wheat protein, 5000 mg of egg protein, and 8000 mg of cow’s milk protein. 9 …”

Section: Maintenance Protocols Including Activity Limitationsmentioning

confidence: 99%

Long term oral immunotherapy management and assessment of success

Wasserman¹

2022

Journal of Food Allergy

Self Cite

View full text Add to dashboard Cite

show abstract

Peanut Oral Immunotherapy: a Current Perspective

Patrawala

Shih

Lee

et al. 2020

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

Purpose of the Review Peanut oral immunotherapy (OIT) is one of the most studied experimental therapies for food allergy. With the recently FDA-approved peanut product, Palforzia, the goal of this article is to review the most recent data from clinical trials, discuss recent trends, and anticipate future developments. Recent Findings The latest research suggests that peanut OIT could be a promising option for peanut-allergic patients, with the majority of participants in research studies achieving the primary efficacy endpoint of desensitization, as well as sustained unresponsiveness in select populations. Some studies also showed improvements in food allergy-related quality of life. However, peanut OIT is not without risk or side effects, including potentially serious allergic reactions. Summary Future research will need to evaluate the short-and long-term effectiveness of the therapy in the real-world setting, predictors of important treatment outcomes, and the use of adjunctive therapies that may mitigate some of these allergic reactions.

show abstract